Hold Rating on Pfizer Amid Political Challenges in Biopharmaceutical Sector

In a report released yesterday, David Risinger from Leerink Partners maintained a Hold rating on Pfizer (PFE – Research Report), with a price target of $26.00.

David Risinger has given his Hold rating due to a combination of factors, primarily focusing on the current political climate in the United States and its impact on the biopharmaceutical industry. Risinger expressed concerns about the U.S. government’s approach towards biotechnology, which he believes is not as supportive as it is towards traditional technology sectors. This environment could potentially hinder innovation and investment in the biotech field, affecting companies like Pfizer.
Despite these challenges, Risinger acknowledges the efforts of Pfizer’s leadership, particularly CEO Albert Bourla, in addressing these issues and advocating for the industry. Bourla emphasized the importance of scientific truth and the global consensus among health authorities on proven medical science. While there are differing views within the U.S. administration, Risinger appreciates the company’s commitment to staying on the right side of history and its role in significant initiatives like Operation Warp Speed. These factors contribute to the decision to maintain a Hold rating on Pfizer’s stock.

In another report released on April 29, Goldman Sachs also maintained a Hold rating on the stock with a $25.00 price target.

Based on the recent corporate insider activity of 27 insiders, corporate insider sentiment is neutral on the stock.